Skip to main content
Quest Diagnostics

White paper - Immuno-oncology

White paper

Immuno-oncology: B-Cell Isotype Switching

Our white paper offers a comprehensive overview of the potential of B-cell isotype switching as a key indicator for adenosine pathway inhibition in cancer treatment.

 

This white paper is free and can be downloaded and read at your convenience.

The innovative medical approach of immunotherapy, harnessing the body's immune system to fight diseases like cancer more effectively. Abstract concept. Generative AI

Transforming care with precision: discover immuno-oncology’s evolution

In this document, we explore the adenosine pathway's critical function in immune system regulation and its implications for tumor growth and immune evasion. By highlighting recent research and clinical findings, we explain how adenosine pathway inhibition can impact immune response, particularly through B-cell activity. This insight is pivotal for pharmaceutical companies and researchers aiming to develop more effective immunotherapeutic strategies.

Furthermore, the white paper elaborates on the assay's prospective application in clinical trials, including its potential to predict patient responsiveness to adenosine pathway-targeted therapies. This aspect is crucial for tailoring treatment plans to individual patients' needs, thereby enhancing the efficacy of cancer immunotherapy.

We invite pharmaceutical partners and research professionals to download and read the full document. It serves as a valuable resource for those committed to exploring innovative approaches to cancer treatment and improving outcomes for patients worldwide.

Join us in examining the implications of B-cell isotype switching for the future of cancer therapy.

Is B-Cell Isotype Switching the Missing Piece in Your Cancer Immuno-oncology puzzle? Let's talk!

694

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.